[F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas

Ken Ichi Watanabe, Hiroaki Nomori, Takashi Ohtsuka, Tsuguo Naruke, Akinori Ebihara, Hideki Orikasa, Kazuto Yamazaki, Kimiichi Uno, Toshiaki Kobayashi, Tomoyuki Goya

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Objective: To predict a malignant grade of lung cancer by fluorodeoxyglucose positron emission tomography (FDG-PET) scanning, we investigated the correlation between FDG uptake and pathological tumor stage, proliferative activities determined by Ki-67 and cyclin D1, and an alteration of p53, in clinical stage (c-stage) IA lung adenocarcinomas. Methods: FDG-PET was performed for 71 patients with c-stage IA lung adenocarcinomas. FDG uptake was measured by a contrast ratio (CR) between the tumor and contralateral lung. Ki-67, cyclin D1 and p53 staining scores were examined by immunohistochemistry. Results: The lesions with ground-glass opacity were found in 26 patients, and solid lesions in 45 by computed tomography. The pathological tumor stages (p-stage) were stage IA in 59 and more advanced stages in 12. The latter had significantly higher CR value than the former (P < 0.001). Patients with CR ≥ 0.55 could be predicted to be at advanced tumor stages, with a sensitivity of 0.83 and a specificity of 0.82. The CR and staining scores of Ki-67 were significantly correlated with each other (P < 0.0001), and both the values were significantly higher in advanced tumor stages than in p-stage IA, and were also significantly higher in tumors with intratumoral lymphatic, vascular and pleural involvements than in those without such features (P < 0.05-0.0001). Conclusions: In c-stage IA lung adenocarcinomas, the FDG uptake can predict p-stage and tumor proliferative activity determined by Ki-67. For c-stage IA lung adenocarcinomas showing CR ≥ 0.55, mediastinoscopy or neoadjuvant chemotherapy is indicated.

Original languageEnglish
Pages (from-to)403-409
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume36
Issue number7
DOIs
Publication statusPublished - 2006 Jul
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Positron-Emission Tomography
Neoplasms
Cyclin D1
Staining and Labeling
Mediastinoscopy
Adenocarcinoma of lung
Glass
Blood Vessels
Lung Neoplasms
Immunohistochemistry
Tomography
Drug Therapy
Lung

Keywords

  • Adenocarcinoma
  • Lung cancer
  • Positron emission tomography
  • Proliferative activity
  • Tumor stage
  • Tumor suppressor gene

ASJC Scopus subject areas

  • Oncology

Cite this

[F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. / Watanabe, Ken Ichi; Nomori, Hiroaki; Ohtsuka, Takashi; Naruke, Tsuguo; Ebihara, Akinori; Orikasa, Hideki; Yamazaki, Kazuto; Uno, Kimiichi; Kobayashi, Toshiaki; Goya, Tomoyuki.

In: Japanese Journal of Clinical Oncology, Vol. 36, No. 7, 07.2006, p. 403-409.

Research output: Contribution to journalArticle

Watanabe, Ken Ichi ; Nomori, Hiroaki ; Ohtsuka, Takashi ; Naruke, Tsuguo ; Ebihara, Akinori ; Orikasa, Hideki ; Yamazaki, Kazuto ; Uno, Kimiichi ; Kobayashi, Toshiaki ; Goya, Tomoyuki. / [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. In: Japanese Journal of Clinical Oncology. 2006 ; Vol. 36, No. 7. pp. 403-409.
@article{994e3668a3804236a51578324cdc1c11,
title = "[F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas",
abstract = "Objective: To predict a malignant grade of lung cancer by fluorodeoxyglucose positron emission tomography (FDG-PET) scanning, we investigated the correlation between FDG uptake and pathological tumor stage, proliferative activities determined by Ki-67 and cyclin D1, and an alteration of p53, in clinical stage (c-stage) IA lung adenocarcinomas. Methods: FDG-PET was performed for 71 patients with c-stage IA lung adenocarcinomas. FDG uptake was measured by a contrast ratio (CR) between the tumor and contralateral lung. Ki-67, cyclin D1 and p53 staining scores were examined by immunohistochemistry. Results: The lesions with ground-glass opacity were found in 26 patients, and solid lesions in 45 by computed tomography. The pathological tumor stages (p-stage) were stage IA in 59 and more advanced stages in 12. The latter had significantly higher CR value than the former (P < 0.001). Patients with CR ≥ 0.55 could be predicted to be at advanced tumor stages, with a sensitivity of 0.83 and a specificity of 0.82. The CR and staining scores of Ki-67 were significantly correlated with each other (P < 0.0001), and both the values were significantly higher in advanced tumor stages than in p-stage IA, and were also significantly higher in tumors with intratumoral lymphatic, vascular and pleural involvements than in those without such features (P < 0.05-0.0001). Conclusions: In c-stage IA lung adenocarcinomas, the FDG uptake can predict p-stage and tumor proliferative activity determined by Ki-67. For c-stage IA lung adenocarcinomas showing CR ≥ 0.55, mediastinoscopy or neoadjuvant chemotherapy is indicated.",
keywords = "Adenocarcinoma, Lung cancer, Positron emission tomography, Proliferative activity, Tumor stage, Tumor suppressor gene",
author = "Watanabe, {Ken Ichi} and Hiroaki Nomori and Takashi Ohtsuka and Tsuguo Naruke and Akinori Ebihara and Hideki Orikasa and Kazuto Yamazaki and Kimiichi Uno and Toshiaki Kobayashi and Tomoyuki Goya",
year = "2006",
month = "7",
doi = "10.1093/jjco/hyl043",
language = "English",
volume = "36",
pages = "403--409",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas

AU - Watanabe, Ken Ichi

AU - Nomori, Hiroaki

AU - Ohtsuka, Takashi

AU - Naruke, Tsuguo

AU - Ebihara, Akinori

AU - Orikasa, Hideki

AU - Yamazaki, Kazuto

AU - Uno, Kimiichi

AU - Kobayashi, Toshiaki

AU - Goya, Tomoyuki

PY - 2006/7

Y1 - 2006/7

N2 - Objective: To predict a malignant grade of lung cancer by fluorodeoxyglucose positron emission tomography (FDG-PET) scanning, we investigated the correlation between FDG uptake and pathological tumor stage, proliferative activities determined by Ki-67 and cyclin D1, and an alteration of p53, in clinical stage (c-stage) IA lung adenocarcinomas. Methods: FDG-PET was performed for 71 patients with c-stage IA lung adenocarcinomas. FDG uptake was measured by a contrast ratio (CR) between the tumor and contralateral lung. Ki-67, cyclin D1 and p53 staining scores were examined by immunohistochemistry. Results: The lesions with ground-glass opacity were found in 26 patients, and solid lesions in 45 by computed tomography. The pathological tumor stages (p-stage) were stage IA in 59 and more advanced stages in 12. The latter had significantly higher CR value than the former (P < 0.001). Patients with CR ≥ 0.55 could be predicted to be at advanced tumor stages, with a sensitivity of 0.83 and a specificity of 0.82. The CR and staining scores of Ki-67 were significantly correlated with each other (P < 0.0001), and both the values were significantly higher in advanced tumor stages than in p-stage IA, and were also significantly higher in tumors with intratumoral lymphatic, vascular and pleural involvements than in those without such features (P < 0.05-0.0001). Conclusions: In c-stage IA lung adenocarcinomas, the FDG uptake can predict p-stage and tumor proliferative activity determined by Ki-67. For c-stage IA lung adenocarcinomas showing CR ≥ 0.55, mediastinoscopy or neoadjuvant chemotherapy is indicated.

AB - Objective: To predict a malignant grade of lung cancer by fluorodeoxyglucose positron emission tomography (FDG-PET) scanning, we investigated the correlation between FDG uptake and pathological tumor stage, proliferative activities determined by Ki-67 and cyclin D1, and an alteration of p53, in clinical stage (c-stage) IA lung adenocarcinomas. Methods: FDG-PET was performed for 71 patients with c-stage IA lung adenocarcinomas. FDG uptake was measured by a contrast ratio (CR) between the tumor and contralateral lung. Ki-67, cyclin D1 and p53 staining scores were examined by immunohistochemistry. Results: The lesions with ground-glass opacity were found in 26 patients, and solid lesions in 45 by computed tomography. The pathological tumor stages (p-stage) were stage IA in 59 and more advanced stages in 12. The latter had significantly higher CR value than the former (P < 0.001). Patients with CR ≥ 0.55 could be predicted to be at advanced tumor stages, with a sensitivity of 0.83 and a specificity of 0.82. The CR and staining scores of Ki-67 were significantly correlated with each other (P < 0.0001), and both the values were significantly higher in advanced tumor stages than in p-stage IA, and were also significantly higher in tumors with intratumoral lymphatic, vascular and pleural involvements than in those without such features (P < 0.05-0.0001). Conclusions: In c-stage IA lung adenocarcinomas, the FDG uptake can predict p-stage and tumor proliferative activity determined by Ki-67. For c-stage IA lung adenocarcinomas showing CR ≥ 0.55, mediastinoscopy or neoadjuvant chemotherapy is indicated.

KW - Adenocarcinoma

KW - Lung cancer

KW - Positron emission tomography

KW - Proliferative activity

KW - Tumor stage

KW - Tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=33748102654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748102654&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyl043

DO - 10.1093/jjco/hyl043

M3 - Article

C2 - 16782729

AN - SCOPUS:33748102654

VL - 36

SP - 403

EP - 409

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 7

ER -